Prednisolone

Chemical formula: C₂₁H₂₈O₅  Molecular mass: 360.444 g/mol  PubChem compound: 5755

Therapeutic indications

Prednisolone is indicated for:

Rheumatoid arthritis

Population group: only adults (18 years old or older)

Rheumatoid arthritis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Ulcerative colitis

Population group: only adults (18 years old or older)

Colitis gravis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Rheumatoid arthritis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Rheumatoid arthritis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Osteoarthritis

Population group: only adults (18 years old or older)

Osteoarthritis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Synovitis

Population group: only adults (18 years old or older)

Synovitis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bursitis

Population group: only adults (18 years old or older)

Bursitis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bronchial asthma

Population group: only adults (18 years old or older)

Airway hyperreactivity

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Anaphylaxis

Population group: only adults (18 years old or older)

Anaphylaxis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Crohn's disease

Population group: only adults (18 years old or older)

Crohn's disease

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Hemorrhagic proctitis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Hemorrhagic proctitis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Crohn's disease

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Crohn's disease

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bronchial asthma

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old)

Airway hyperreactivity

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Hypersensitivity reaction

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Hypersensitivity reaction

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Serum sickness caused by drug

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Serum sickness caused by drug

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Angioneurotic oedema

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Angioedema

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Anaphylaxis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Anaphylaxis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Giant cell arteritis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Temporal arteritis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Polymyalgia rheumatica

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Polymyalgia rheumatica

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Mixed collagen vascular disease

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Mixed collagen vascular disease

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Polyarteritis nodosa

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Polyarteritis nodosa

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Polymyositis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Polymyositis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Autoimmune hemolytic anemia

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Autoimmune hemolytic anemia

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Lymphoid leukemia

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Lymphatic leukaemia

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Lymphoma

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Malignant lymphoma

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Multiple myeloma

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Multiple myeloma (clinical)

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Idiopathic thrombocytopenic purpura

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Chronic idiopathic thrombocytopenic purpura

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Postmyocardial infarction syndrome

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

† Postmyocardial infarction syndrome

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute rheumatic fever with valvulitis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Acute rheumatic fever with valvulitis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Adrenal insufficiency

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Adrenal cortical hypofunction

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Congenital adrenal hyperplasia

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Congenital adrenal hyperplasia

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Celiac syndrome

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Coeliac disease

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Autoimmune hepatitis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Autoimmune hepatitis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Sarcoidosis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Sarcoidosis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Hyperpyrexia

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Hyperpyrexia

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Behcet's syndrome

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Behcet's syndrome

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Pemphigus vulgaris

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Pemphigus vulgaris

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Exfoliative dermatitis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Erythroderma

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Bullous pemphigoid

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Bullous pemphigoid

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Systemic lupus erythematosus

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Systemic lupus erythematosus

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Dermatomyositis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Dermatomyositis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Allergic pneumonitis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Extrinsic allergic alveolitis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Asthma

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Airway hyperreactivity

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Pulmonary aspergillosis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Pulmonary aspergillosis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Pulmonary fibrosis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Fibrosis of lung

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Pulmonary alveolitis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Simple pulmonary alveolitis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Foreign body in respiratory tract

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Foreign body in respiratory tract

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Adult respiratory distress syndrome

Population group: only adults (18 years old or older)

Adult respiratory distress syndrome

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Spasmodic croup

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Recurrent allergic croup

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Lupus nephritis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

SLE glomerulonephritis syndrome

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Acute interstitial nephritis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Acute interstitial nephritis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Minimal change glomerulonephritis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Minimal change disease

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Scleritis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Scleritis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Posterior uveitis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Posterior uveitis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Retinal vasculitis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Retinal vasculitis

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Infantile spasms

Population group: only infants (40 days - 1 year old)

† Infantile spasm

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Shy-Drager syndrome

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Multiple system atrophy

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Subacute inflammatory demyelinating polyradiculoneuropathy

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Subacute idiopathic demyelinating polyradiculoneuropathy

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Prednisolone is contraindicated in the following cases:

Vaccination with live vaccines

at least one of
Cholera, live attenuated
Influenza, live attenuated
Measles, combinations with mumps and rubella, live attenuated
Measles, combinations with mumps, live attenuated
Measles, combinations with mumps, rubella and varicella, live attenuated
Measles, combinations with rubella, live attenuated
Measles, live attenuated
Mumps, live attenuated
Poliomyelitis oral, monovalent live attenuated
Poliomyelitis oral, trivalent, live attenuated
Rota virus, live attenuated
Rubella, combinations with mumps, live attenuated
Rubella, live attenuated
Tuberculosis, live attenuated
Typhoid, oral, live attenuated
Varicella, live attenuated
Yellow fever, live attenuated
Zoster, live attenuated

Infection

Infectious disease

Ocular herpes simplex

Ophthalmic herpes simplex

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2017: PREDNISOLONE Suppositories
Structured Product Labeling (SPL) 2019: PRED MILD Eye-drops, suspension
Structured Product Labeling (SPL) 2020: PEDIAPRED Oral solution
Summary of Product Characteristics (SPC) 2017: MINIMS PREDNISOLONE Single-use eye drops
Summary of Product Characteristics (SPC) 2017: PREDNISOLONE Suspension for injection
Structured Product Labeling (SPL) 2020: PRED FORTE Eye drops, suspension
Summary of Product Characteristics (SPC) 2018: PREDNISOLONE Tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈